TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7881027

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Famotidine (80 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Sucralfate (1000 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Vitamin A (3 x 50,000 IU/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Cyproheptadinum (3 x 4 mg/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: DE‐NOL (3 x 5 mL/day)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Tisacid (Al‐Mg‐hydroxycarbonicum; in different doses)
Number of subjects: 441
Study: 3355243

Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ozone (0.21 ppm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 15
Study: 29740980

Group type: EXPERIMENTAL
Intervention: Coping planning intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Comparison group (repetition of interventions from first intervention phase)
Number of subjects: 177
Study: 28449657

Group type: EXPERIMENTAL
Intervention: Denosumab treatment
Number of subjects: 0
Study: 25646297

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 29
Study: 22537517

Group type: EXPERIMENTAL
Intervention: u‐HA/PLLA plate
Number of subjects: 60

Group type: COMPARATOR
Intervention: PLLA plate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 60
Study: 20595145

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 μg, 2 × 2 inhalations b.i.d.
Number of subjects: 8424

Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 μg, 1 × 2 inhalations b.i.d.
Number of subjects: 8424
Study: 17874255

Group type: EXPERIMENTAL
Intervention: Armodafinil (150 or 250 mg)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study: 16884571

Group type: EXPERIMENTAL
Intervention: Home telecare service
Number of subjects: 653

Group type: COMPARATOR
Intervention: Face-to-face nurse visiting service
Number of subjects: 653
Study: 12791115

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg.kg‐1 plus magnesium sulphate 30 mg.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10990037

Group type: EXPERIMENTAL
Intervention: Diabetics with pre-proliferative/proliferative retinopathy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diabetics with no retinopathy/background changes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 62
Study: 8998681

Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin (25 patients)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (23 patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calcitonin plus calcium
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo plus calcium
Number of subjects: 48
Study: 1600053

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pantoprazole 60 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6327141

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lymphocyte receptor numbers
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoprenaline stimulation
Number of subjects: 11
Study: 30782680

Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone) with hyaluronic acid (HA) injection
Number of subjects: 146

Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone) injection
Number of subjects: 146
Study: 30083724

Group type: EXPERIMENTAL
Intervention: Infants with hearing aids (HAs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Infants with normal hearing (NH)
Number of subjects: 42
Study: 27577510

Group type: EXPERIMENTAL
Intervention: Group A (270 mg I/mL iodixanol)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B (320 mg I/mL iodixanol)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (320 mg I/mL iodixanol, conventional retrospective ECG gating mode)
Number of subjects: 90
Study: 24522334

Group type: EXPERIMENTAL
Intervention: Varenicline (N=296)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Nicotine patch (N=291)
Number of subjects: 587
Study: 20964565

Group type: EXPERIMENTAL
Intervention: 5% spironolactone gel
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 19223621

Group type: EXPERIMENTAL
Intervention: ST-246 administered at 10 mg/kg/day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ST-246 administered at 3 mg/kg to 100 mg/kg once a day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dosage of ST-246 400 mg once daily for 14 days
Number of subjects: 0
Study: 17502345

Group type: EXPERIMENTAL
Intervention: Perineal/genital cleaning with soap
Number of subjects: 350

Group type: COMPARATOR
Intervention: No cleaning of the perineum
Number of subjects: 350
Study: 15325892

Group type: EXPERIMENTAL
Intervention: 0.5% C31G
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1.7% C31G
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 61
Study: 11251703

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 17

Group type: COMPARATOR
Intervention: Active placebo (trihexyphenidyl)
Number of subjects: 17
Study: 9704763

Group type: EXPERIMENTAL
Intervention: Monophasic gestodene
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Triphasic gestodene
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 99
Study: 8053615

Group type: EXPERIMENTAL
Intervention: Cholestyramine (8 g twice daily)
Number of subjects: 21
Study: 3270328

Group type: EXPERIMENTAL
Intervention: Cocaine infusion (IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline solution infusion)
Number of subjects: 0
Study: 29730540

Group type: EXPERIMENTAL
Intervention: Target sequence (10 trials)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Target sequence (10 trials) + distractor sequences (3 trials)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Excluding first-trial data (silent practice trial)
Number of subjects: 212
Study: 26619355

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prophylactic placebo cream
Number of subjects: 50
Study: 24919692

Group type: EXPERIMENTAL
Intervention: Dietary protein supplementation (20.7 g of protein, 9.3 g of carbohydrate, and 3.0 g of fat) twice daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (PRO and CON)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PRO group only
Number of subjects: 23
Study: 22624502

Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg every 12 hours for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Danoprevir 100 mg alone
Number of subjects: 0
Study: 20883290

Group type: EXPERIMENTAL
Intervention: Sodium salicylate (SS)
Number of subjects: 0
Study: 18928104

Group type: EXPERIMENTAL
Intervention: Rupi Xiaosan Recipe (RPXSR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rukang Tablet (RKT)
Number of subjects: 100
Study: 16629762

Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 90

Group type: COMPARATOR
Intervention: Avonex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rebif
Number of subjects: 90
Study: 12747193

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus traditional Chinese medicine (TCM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 47
Study: 10805507

Group type: EXPERIMENTAL
Intervention: Dissociated diet (food combining)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Balanced diet
Number of subjects: 54
Study: 9101956

Group type: EXPERIMENTAL
Intervention: 3-D vision system
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-D vision system
Number of subjects: 0
Study: 1602793

Group type: EXPERIMENTAL
Intervention: Modified LSA2L2 therapy with less intensive intrathecal chemotherapy and no radiotherapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Modified LSA2L2 therapy with intensified intrathecal therapy and radiotherapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: T‐cell 2 therapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Modified LSA2L2 therapy (with or without intensified intrathecal chemotherapy and radiotherapy)
Number of subjects: 193
Study: 3913377

Group type: EXPERIMENTAL
Intervention: Absolute ethanol embolization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gelfoam embolization
Number of subjects: 30
Study: 30107586

Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We intervention (8-month campaign delivered by child care centers with branded materials)
Number of subjects: 0
Study: 29144061

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 26923491

Group type: EXPERIMENTAL
Intervention: Daily review of antimicrobial use
Number of subjects: 0
Study: 25344703

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (6 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Recreational group discussion (control)
Number of subjects: 40
Study: 22828921

Group type: EXPERIMENTAL
Intervention: G. glauca herbal medicinal product (0.175 mg of galphimine-B, one or two capsules twice a day for 12 weeks plus 3 withdrawal weeks)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Lorazepam (0.5 mg with the same presentation and posology)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: G. glauca herbal medicinal product
Number of subjects: 191
Study: 20225073

Group type: EXPERIMENTAL
Intervention: Combined posterior lumbar plexus (PLP) and sciatic nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of femoral, lateral femoral cutaneous, and sciatic nerve blocks with obturator nerve block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous postoperative PLP block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 0
Study: 18632241

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 44
Study: 16802896

Group type: EXPERIMENTAL
Intervention: Target group (n = 133) with intervention including videotaped examples, problem-solving activities, and self-critique through video procedures across 10 home visits.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Developmental feedback comparison group (n = 131) as control.
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Target group (n = 133) with intervention.
Number of subjects: 264
Study: 14669193

Group type: EXPERIMENTAL
Intervention: Electric muscle stimulation (EMS) of the vastus medialis muscle for 4 hours a day, starting on postoperative day 2, over the first 6 postoperative weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 30
Study: 10949680

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg-1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam (100 micrograms kg-1)
Number of subjects: 30
Study: 8848991

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 31
Study: 1375648

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% applied 4 times daily for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 4024019

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 5 mg/kg
Number of subjects: 12
Study: 31912649

Group type: EXPERIMENTAL
Intervention: Early market access to iodized salt
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control (later access to iodized salt)
Number of subjects: 1220
Study: 29725747

Group type: EXPERIMENTAL
Intervention: Patient-specific instruments (PSI)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 163
Study: 28166129

Group type: EXPERIMENTAL
Intervention: Novice (NOV) group
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Experienced (EXP) group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 95
Study: 25959877

Group type: COMPARATOR
Intervention: Sevoflurane group (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isoflurane group (n = 32)
Number of subjects: 64
Study: 23421857

Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 23
Study: 21617554

Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus Ayurvedic placebo (n = 14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ayurveda plus MTX placebo (n = 12)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ayurveda plus MTX (n = 17)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Adverse events in MTX group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adverse events in Ayurveda group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adverse events in combination group
Number of subjects: 43
Study: 18422727

Group type: EXPERIMENTAL
Intervention: 0.2 mg p277
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.0 mg p277
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5 mg p277
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16543910

Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg/day
Number of subjects: 37

Group type: COMPARATOR
Intervention: atenolol 50-100 mg/day
Number of subjects: 37
Study: 15017529

Group type: EXPERIMENTAL
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination antihypertensive therapy including ACE inhibitors or ARBs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study: 11195999

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 9322717

Group type: EXPERIMENTAL
Intervention: Saline lavage
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antiseptic or antibiotic lavage
Number of subjects: 152

Group type: COMPARATOR
Intervention: No saline lavage (control group)
Number of subjects: 152
Study: 8258115

Group type: EXPERIMENTAL
Intervention: Thoracic epidural morphine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lumbar epidural morphine
Number of subjects: 22
Study: 3888367

Group type: EXPERIMENTAL
Intervention: Combination regimen (prochlorperazine, dexamethasone, pentobarbital)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 27
Study: 30915573

Group type: EXPERIMENTAL
Intervention: MRI-DWI in abscess group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (routine postoperative MRI-DWI)
Number of subjects: 19
Study: 29533303

Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus atazanavir/ritonavir
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus darunavir/ritonavir
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus raltegravir
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: plasma OPG levels at week 48 and 96
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: plasma RANKL and RANKL/OPG ratio levels
Number of subjects: 234
Study: 27687537

Group type: EXPERIMENTAL
Intervention: Weight loss + 2000IU oral vitamin D3/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Weight loss + daily placebo
Number of subjects: 100
Study: 25252818

Group type: EXPERIMENTAL
Intervention: Change in skirt size (CSS) per 10 years
Number of subjects: 92834

Group type: EXPERIMENTAL
Intervention: Current skirt size at study entry
Number of subjects: 92834

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at recruitment
Number of subjects: 92834

Group type: EXPERIMENTAL
Intervention: Change in skirt size (CSS) and BMI in the model
Number of subjects: 92834
Study: 22404114

Group type: EXPERIMENTAL
Intervention: Cis-atracurium (CIS) 0.15 mg/kg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Succinylcholine (SUC) 1 mg/kg
Number of subjects: 65
Study: 20471549

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over the hand area of the M1 for 20 minutes at 1mA for five consecutive days.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham tDCS applied over the hand area of the M1 for 20 minutes at 1mA for five consecutive days.
Number of subjects: 21
Study: 16880195

Group type: EXPERIMENTAL
Intervention: Behavioural graded activity (97 patients)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (103 patients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Behavioural graded activity
Number of subjects: 200

Group type: COMPARATOR
Intervention: Behavioural graded activity vs Usual care
Number of subjects: 200
Study: 15661840

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with local heating at 41 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with local heating at 43 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise in hyperthermic condition
Number of subjects: 0
Study: 12447292

Group type: EXPERIMENTAL
Intervention: Water instillation (500 to 1000 mL) at the beginning of the procedure
Number of subjects: 259

Group type: COMPARATOR
Intervention: Conventional colonoscopy (control group)
Number of subjects: 259
Study: 10534595

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo needling
Number of subjects: 52
Study: 7793821

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active form of vitamin D3 (1,25(OH)2D3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic analogue MC‐903
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic analogue EB 1089
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 0
Study: 2354386

Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque 350)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Iopamidol (Isovue 370)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix 320)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Arterial injections
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Peripheral venous injections
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Central venous injections
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Subset of 80 patients with elevated baseline creatinine
Number of subjects: 500
Study: 512017

Group type: EXPERIMENTAL
Intervention: Covert modeling
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Behavior rehearsal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Generalization of assertive skills
Number of subjects: 24
Study: 31382981

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg intravenously prior to skin incision
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg intravenously after clamping of the umbilical cord
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaginally born infants (control group)
Number of subjects: 40
Study: 29477817

Group type: EXPERIMENTAL
Intervention: Serum uric acid levels >7.2 mg/dl
Number of subjects: 6683

Group type: EXPERIMENTAL
Intervention: Serum uric acid levels ≥7 mg/dl
Number of subjects: 6683
Study: 28925134

Group type: EXPERIMENTAL
Intervention: Longxue Tongluo capsule (two capsules each time, three times daily for 4 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (two capsules each time, three times daily for 4 weeks)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Longxue Tongluo capsule
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 25402168

Group type: EXPERIMENTAL
Intervention: Replacement of regular‐fat dairy foods with reduced‐fat or low‐fat items
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 114
Study: 23072975

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for social anxiety disorder
Number of subjects: 0
Study: 19293729

Group type: EXPERIMENTAL
Intervention: Moxibustion 1
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Moxibustion 2
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 51
Study: 17134770

Group type: EXPERIMENTAL
Intervention: Trimethazidine (TMZ) 20 mg, tds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16794519

Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MIBG scintigraphy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MRI + MIBG scintigraphy
Number of subjects: 32
Study: 12085250

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 30
Study: 9459518

Group type: EXPERIMENTAL
Intervention: 5‐cm H2O PEEP
Number of subjects: 22

Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 22